Skip to main content
News

GSK to receive CARB-X funding to develop superbug vaccines – EPM Magazine

By March 8, 2021No Comments
GSK Logo

GSK Logo

GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH) are currently working on two vaccine projects. The first is to prevent Group A Streptococcus infections, commonly known as Strep Throat, which is a major reason for antibiotic prescriptions and cause of immune-mediated diseases. 

The second project GSK is working is a vaccine to prevent infections caused by Salmonella enterica, which cause Invasive nontyphoidal salmonellosis (iNTS) disease and typhoid fever, major causes of death among children and significant health challenges primarily in sub-Saharan African countries. 

 

{iframe}https://www.epmmagazine.com/news/gsk-to-receive-carb-x-funding-to/{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.